How the same cancer driver mutations can manifest differently across the lifespan

Recently an article by Vivek Subbiah and Razelle Kurzrock was published in Cancer Cell.

“Precision oncology across the ages: Impact on children, adolescents, and young adults”

Oncologists have been commenting on the article on social media:

Eric Topol, Founder and Director of the Scripps Research Translational Institute:

“How the same cancer driver mutations can manifest differently across the lifespan”

Vivek Subbiah:

“Hot off the press.

Pleased to share with the world our commentary published in Cancer Cell.

• Precision oncology across the ages: Impact on children, adolescents, and young adults
• PrecisionOncology Is Age and Tissue-Agnostic.”

Razelle Kurzrock:

“Ha ha. When Eric Topol posts our paper before I even knew it was already published.”

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.

Razelle Kurzrock is the Chief Medical Officer at ACT Genomics, Senior Deputy Director at the HKSH Cancer Centre, and Senior Advisor at CureScience. She is also a Professor of Medicine at the University of California, San Diego (UCSD) and the Director of the Center for Personalized Cancer Therapy at UCSD.

Additionally, Dr. Kurzrock is the founding director of the Michels Rare Cancers Research Laboratories at the MCW Cancer Center. Renowned as one of the world’s top 25 voices in precision medicine, she is celebrated for her contributions, of having over 950 scientific and medical publications.